Apellis Pharmaceuticals, Inc. (APLS)

Market Cap	3.98B
Revenue (ttm)	715.22M
Net Income (ttm)	-250.10M
Shares Out	124.39M
EPS (ttm)	-2.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	74,653
Open	32.13
Previous Close	32.68
Day's Range	31.95 - 32.49
52-Week Range	24.34 - 73.80
Beta	0.92
Analysts	Buy
Price Target	49.89 (+55.91%)
Earnings Date	Nov 5, 2024

About APLS

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 9, 2017
• Employees: 706
• Stock Exchange: NASDAQ
• Ticker Symbol: APLS
• Website: https://www.apellis.com

Financial Performance

In 2023, Apellis Pharmaceuticals's revenue was $396.59 million, an increase of 425.83% compared to the previous year's $75.42 million. Losses were -$528.63 million, -18.94% less than in 2022.

Analyst Forecast

According to 19 analysts, the average rating for APLS stock is "Buy." The 12-month stock price forecast is $49.89, which is an increase of 55.91% from the latest price.

Price Target

$49.89

(55.91% upside)

Analyst Consensus: Buy